IMI Members

EU Logo efpia logo

IMI Ongoing Projects

The Innovative Medicines Initiative (IMI) now has 47 projects that are up and running as a result of the successful launches of its first eight Calls for proposals.

Click on projects acronyms for more details

All Projects

- ABIRISK

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk

- ADVANCE

Accelerated development of vaccine benefit-risk collaboration in Europe

- AETIONOMY

Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy

- BioVacSafe

Biomarkers for Enhanced Vaccine Immunosafety

- BTCure

Be The Cure

- CHEM21

Chemical manufacturing methods for the 21st century pharmaceutical industries

- COMBACTE

Combatting Bacterial Resistance in Europe

- COMPACT

Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets

- DDMoRe

Drug Disease Model Resources     

- DIRECT

Diabetes research on patient stratification

- EBiSC

European Bank for induced pluripotent Stem Cells

- EHR4CR

Electronic Health Records Systems for Clinical Research

- ELF

European Lead Factory

- EMIF

European Medical Information Framework

- EMTRAIN

European Medicines Research Training Network  

- ENABLE

European Gram-negative Antibacterial Engine

- eTOX

Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities  

- eTRIKS

Delivering European Translational Information & Knowledge Management Services

- EU-AIMS

European Autism Interventions - a Multicentre Study for Developing New Medications

- Eu2P

European programme in Pharmacovigilance and Pharmacoepidemiology

- EUPATI

European Patients' Academy on Therapeutic Innovation

- EUROPAIN

Understanding chronic pain and improving its treatment

- GETREAL

Incorporating real-life clinical data into drug development

- IMIDIA

Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes

- K4DD

Kinetics for Drug Discovery

- MARCAR

Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis

- MIP-DILI

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury

- ND4BB

New Drugs for Bad Bugs

- NEWMEDS

Novel methods leading to new medications in depression and schizophrenia

- Onco Track

Methods for systematic next generation oncology biomarker development

- Open PHACTS

The Open Pharmacological Concepts Triple Store

- ORBITO

Oral biopharmaceutics tools

- Pharma-Cog

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development  

- Pharmatrain

Pharmaceutical Medicine Training Programme

- PRECISESADS

Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases

- Predect

New models for preclinical evaluation of drug efficacy in common solid tumours  

- PreDiCT-TB

Model-based preclinical development of anti-tuberculosis drug combinations

- PRO-active

Physical Activity as a Crucial Patient Reported Outcome in COPD

- PROTECT

Pharmacoepidemiological research on outcomes of therapeutics by a European consortium  

- Quic-Concept

Quantative imaging in cancer:connecting cellular process with therapy    

- RAPP-ID

Development of rapid point-of-care test platforms for infectious diseases  

- SAFE-T

Safer and Faster Evidence-based Translation

- SafeSciMET

European Modular Education and Training Programme in Safety Sciences for Medicines

- STEMBANCC

Stem cells for biological assays of novel drugs and predictive toxicology

- SUMMIT

Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools

- TRANSLOCATION

Molecular basis of the bacterial cell wall permeability

- U-BIOPRED

Unbiased biomarkers for the prediction of respiratory disease outcomes